In her commentary, in JAMA Neurology, Thiara describes how animal studies have shown that GLP-1 may increase “synaptic plasticity,” the way the brain rewires its network to change how information is processed and stored. The drugs also show promise in reducing inflammation, free radicals, and damage to neurons, which are key factors in neurodegenerative diseases.